A first Phase II study of IONIS-FB-LRx in patients with dry age-related macular degeneration (AMD).

Trial Profile

A first Phase II study of IONIS-FB-LRx in patients with dry age-related macular degeneration (AMD).

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs IONIS-FB-LRX (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2017 New trial record
    • 11 Aug 2017 According to an Ionis Pharmaceuticals media release, company plans to initiate this study later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top